BOSTON, MA—(UPDATED) Patients with severe symptomatic degenerative mitral regurgitation (MR) ineligible for surgery fare just as well when treated with the Pascal device (Edwards Lifesciences) as ...

PHOENIX, AZ—The largest, echo core lab-adjudicated analysis of the late-generation MitraClips to date offers reassuring signs that the newest iterations of this transcatheter edge-to-edge repair (TEER ...

Abbott Laboratories, Inc. ABT recently presented late-breaking data from the Landmark COAPT trial for MitraClip, demonstrating the long-term benefits of the device in patients fighting heart failure.

The US Food and Drug Administration (FDA) has expanded the indication for the MitraClip (Abbott) device to include patients with normal mitral valves who develop symptoms of heart failure and moderate ...

Surgical repair decreased MR more than MitraClip ®. In 12-month follow-up, 20% of MitraClip patients required surgery for mitral dysfunction versus 2% in surgical patients. Both groups had ...

- CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology - MitraClip is a first-of-its-kind ...

The post-approval study evaluating the safety and efficacy of MitraClip in a real-world, commercial setting was presented today as late-breaking clinical science at the Society for Cardiovascular ...

WASHINGTON, D.C., Oct. 24, 2007 – The vast majority of patients who had a successful result with the percutaneous MitraClip device did not need mitral valve surgery three years after their procedure, ...

In 2016, medical device giant Abbott issued a recall for its MitraClip cardiac device — “a Class I recall, the most serious type,” the FDA said. “Use of this device may cause serious injuries or death ...